Biomedical Decision Intelligence for Biotech
We track and interpret evolving biomedical evidence to clarify uncertainty and its implications for therapeutic development, partnering, and portfolio decisions. Our initial focus is on rare diseases.
How It Works
1. Monitor
Track scientific, clinical, regulatory, and competitive developments over time to identify what has changed.
What We Do
2. Structure
Organize public evidence with traceable sources and the context needed to interpret it.
↓
↓
3. Analyze
Examine emerging patterns, evidence limitations, and unresolved questions.
↓
4. Inform
Clarify implications for therapeutic development, partnering, and portfolio decisions.
Capta Bio combines an internal AI-assisted intelligence system with founder-led analysis to interpret evolving biomedical evidence.
Our approach focuses on what has changed, why it matters, what uncertainty remains, and how new developments may influence strategic decisions. Our published Strategic Insights illustrate this approach across rare-disease therapeutic landscapes.
Rare Disease Intelligence
Structured monitoring and interpretation of therapeutic, clinical, and strategic developments.
Business Development Intelligence
Support opportunity assessment and partnership evaluation.
Competitive Intelligence
Track meaningful signals across emerging therapeutic landscapes.
Decision Support
Transform fragmented information into actionable strategic insights
Therapeutic Development Leaders
Business Development Teams
Corporate Strategy Leaders
Biotech Founders
Portfolio Decision Makers
Our work is relevant to biotech leaders evaluating therapeutic development, partnering, and portfolio decisions.
Who This Is For
Discuss a Strategic Question
What evidence could change your next development, partnering, or portfolio decision?
Share the therapeutic area and question you are considering. We can discuss whether a founder-led assessment would be useful.